Celltrion Changes Late-Stage Trial Plans on Drug Copy
This article is for subscribers only.
Celltrion Inc. postponed a late-stage trial of a biosimilar version of Roche Holding AG’s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis AG.
Celltrion will pursue phase III tests after it completes phase I this month, and not at the same time, on the advice of some state regulators, the Inchon, South Korea-based company said in a statement on its website. Celltrion wasn’t available for further comment after business hours today.